id	sid	tid	token	lemma	pos
dhrp-29	1	1	2021	2021	NUM
dhrp-29	1	2	,	,	PUNCT
dhrp-29	1	3	vol	vol	NOUN
dhrp-29	1	4	.	.	NOUN
dhrp-29	1	5	1	1	NUM
dhrp-29	1	6	(	(	PUNCT
dhrp-29	1	7	s4	s4	PROPN
dhrp-29	1	8	)	)	PUNCT
dhrp-29	1	9	20	20	NUM
dhrp-29	1	10	-	-	SYM
dhrp-29	1	11	21	21	NUM
dhrp-29	1	12	https://doi.org/10.47488/dhrp.v1is4.29	https://doi.org/10.47488/dhrp.v1is4.29	NOUN
dhrp-29	1	13	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-29	1	14	20	20	NUM
dhrp-29	1	15	©	©	PROPN
dhrp-29	1	16	dhr	dhr	PROPN
dhrp-29	1	17	health	health	PROPN
dhrp-29	1	18	institute	institute	PROPN
dhrp-29	1	19	for	for	ADP
dhrp-29	1	20	research	research	NOUN
dhrp-29	1	21	and	and	CCONJ
dhrp-29	1	22	development	development	NOUN
dhrp-29	1	23	editorial	editorial	NOUN
dhrp-29	1	24	will	will	AUX
dhrp-29	1	25	molnupiravir	molnupiravir	PROPN
dhrp-29	1	26	be	be	AUX
dhrp-29	1	27	the	the	DET
dhrp-29	1	28	first	first	ADJ
dhrp-29	1	29	oral	oral	ADJ
dhrp-29	1	30	treatment	treatment	NOUN
dhrp-29	1	31	for	for	ADP
dhrp-29	1	32	high	high	ADJ
dhrp-29	1	33	-	-	PUNCT
dhrp-29	1	34	risk	risk	NOUN
dhrp-29	1	35	nonhospitalized	nonhospitalize	VERB
dhrp-29	1	36	patients	patient	NOUN
dhrp-29	1	37	with	with	ADP
dhrp-29	1	38	mild	mild	ADJ
dhrp-29	1	39	-	-	PUNCT
dhrp-29	1	40	moderate	moderate	ADJ
dhrp-29	1	41	covid-19	covid-19	PROPN
dhrp-29	1	42	?	?	PUNCT
dhrp-29	2	1	the	the	DET
dhrp-29	2	2	first	first	ADJ
dhrp-29	2	3	case	case	NOUN
dhrp-29	2	4	of	of	ADP
dhrp-29	2	5	sars	sar	NOUN
dhrp-29	2	6	-	-	PUNCT
dhrp-29	2	7	cov-2	cov-2	NOUN
dhrp-29	2	8	infection	infection	NOUN
dhrp-29	2	9	in	in	ADP
dhrp-29	2	10	united	united	PROPN
dhrp-29	2	11	states	states	PROPN
dhrp-29	2	12	was	be	AUX
dhrp-29	2	13	confirmed	confirm	VERB
dhrp-29	2	14	on	on	ADP
dhrp-29	2	15	january	january	PROPN
dhrp-29	2	16	19	19	NUM
dhrp-29	2	17	,	,	PUNCT
dhrp-29	2	18	2020	2020	NUM
dhrp-29	2	19	,	,	PUNCT
dhrp-29	2	20	in	in	ADP
dhrp-29	2	21	a	a	DET
dhrp-29	2	22	man	man	NOUN
dhrp-29	2	23	who	who	PRON
dhrp-29	2	24	had	have	AUX
dhrp-29	2	25	returned	return	VERB
dhrp-29	2	26	home	home	ADV
dhrp-29	2	27	to	to	ADP
dhrp-29	2	28	snohomish	snohomish	PROPN
dhrp-29	2	29	county	county	PROPN
dhrp-29	2	30	,	,	PUNCT
dhrp-29	2	31	washington	washington	PROPN
dhrp-29	2	32	on	on	ADP
dhrp-29	2	33	january	january	PROPN
dhrp-29	2	34	15	15	NUM
dhrp-29	2	35	,	,	PUNCT
dhrp-29	2	36	2020	2020	NUM
dhrp-29	2	37	,	,	PUNCT
dhrp-29	2	38	after	after	ADP
dhrp-29	2	39	traveling	travel	VERB
dhrp-29	2	40	to	to	ADP
dhrp-29	2	41	wuhan	wuhan	PROPN
dhrp-29	2	42	,	,	PUNCT
dhrp-29	2	43	china	china	PROPN
dhrp-29	2	44	.	.	PUNCT
dhrp-29	3	1	since	since	SCONJ
dhrp-29	3	2	the	the	DET
dhrp-29	3	3	outbreak	outbreak	NOUN
dhrp-29	3	4	of	of	ADP
dhrp-29	3	5	this	this	DET
dhrp-29	3	6	pandemic	pandemic	ADJ
dhrp-29	3	7	,	,	PUNCT
dhrp-29	3	8	significant	significant	ADJ
dhrp-29	3	9	progress	progress	NOUN
dhrp-29	3	10	has	have	AUX
dhrp-29	3	11	been	be	AUX
dhrp-29	3	12	made	make	VERB
dhrp-29	3	13	in	in	ADP
dhrp-29	3	14	the	the	DET
dhrp-29	3	15	development	development	NOUN
dhrp-29	3	16	of	of	ADP
dhrp-29	3	17	vaccines	vaccine	NOUN
dhrp-29	3	18	that	that	PRON
dhrp-29	3	19	are	be	AUX
dhrp-29	3	20	used	use	VERB
dhrp-29	3	21	in	in	ADP
dhrp-29	3	22	preventing	prevent	VERB
dhrp-29	3	23	sars	sar	NOUN
dhrp-29	3	24	-	-	PUNCT
dhrp-29	3	25	cov-2	cov-2	PART
dhrp-29	3	26	infection	infection	NOUN
dhrp-29	3	27	.	.	PUNCT
dhrp-29	4	1	to	to	ADP
dhrp-29	4	2	date	date	NOUN
dhrp-29	4	3	,	,	PUNCT
dhrp-29	4	4	over	over	ADP
dhrp-29	4	5	392	392	NUM
dhrp-29	4	6	million	million	NUM
dhrp-29	4	7	doses	dose	NOUN
dhrp-29	4	8	of	of	ADP
dhrp-29	4	9	the	the	DET
dhrp-29	4	10	three	three	NUM
dhrp-29	4	11	vaccines	vaccine	NOUN
dhrp-29	4	12	approved	approve	VERB
dhrp-29	4	13	under	under	ADP
dhrp-29	4	14	the	the	DET
dhrp-29	4	15	emergency	emergency	NOUN
dhrp-29	4	16	use	use	NOUN
dhrp-29	4	17	authorization	authorization	NOUN
dhrp-29	4	18	(	(	PUNCT
dhrp-29	4	19	eua	eua	PROPN
dhrp-29	4	20	)	)	PUNCT
dhrp-29	4	21	have	have	AUX
dhrp-29	4	22	been	be	AUX
dhrp-29	4	23	administered	administer	VERB
dhrp-29	4	24	in	in	ADP
dhrp-29	4	25	the	the	DET
dhrp-29	4	26	united	united	PROPN
dhrp-29	4	27	states	states	PROPN
dhrp-29	4	28	(	(	PUNCT
dhrp-29	4	29	1	1	NUM
dhrp-29	4	30	)	)	PUNCT
dhrp-29	4	31	.	.	PUNCT
dhrp-29	5	1	given	give	VERB
dhrp-29	5	2	the	the	DET
dhrp-29	5	3	safety	safety	NOUN
dhrp-29	5	4	and	and	CCONJ
dhrp-29	5	5	efficacy	efficacy	NOUN
dhrp-29	5	6	of	of	ADP
dhrp-29	5	7	pfizer	pfizer	NOUN
dhrp-29	5	8	/	/	SYM
dhrp-29	5	9	biontech	biontech	PROPN
dhrp-29	5	10	mrnabased	mrnabase	VERB
dhrp-29	5	11	vaccine	vaccine	NOUN
dhrp-29	5	12	and	and	CCONJ
dhrp-29	5	13	after	after	ADP
dhrp-29	5	14	rigorous	rigorous	ADJ
dhrp-29	5	15	scientific	scientific	ADJ
dhrp-29	5	16	review	review	NOUN
dhrp-29	5	17	of	of	ADP
dhrp-29	5	18	available	available	ADJ
dhrp-29	5	19	data	datum	NOUN
dhrp-29	5	20	,	,	PUNCT
dhrp-29	5	21	u.s	u.s	PROPN
dhrp-29	5	22	.	.	PROPN
dhrp-29	5	23	food	food	PROPN
dhrp-29	5	24	and	and	CCONJ
dhrp-29	5	25	drug	drug	PROPN
dhrp-29	5	26	administration	administration	PROPN
dhrp-29	5	27	(	(	PUNCT
dhrp-29	5	28	fda	fda	PROPN
dhrp-29	5	29	)	)	PUNCT
dhrp-29	5	30	has	have	AUX
dhrp-29	5	31	fully	fully	ADV
dhrp-29	5	32	approved	approve	VERB
dhrp-29	5	33	this	this	DET
dhrp-29	5	34	vaccine	vaccine	NOUN
dhrp-29	5	35	which	which	PRON
dhrp-29	5	36	is	be	AUX
dhrp-29	5	37	now	now	ADV
dhrp-29	5	38	marketed	market	VERB
dhrp-29	5	39	under	under	ADP
dhrp-29	5	40	the	the	DET
dhrp-29	5	41	brand	brand	NOUN
dhrp-29	5	42	name	name	NOUN
dhrp-29	5	43	comirnaty	comirnaty	NOUN
dhrp-29	5	44	for	for	ADP
dhrp-29	5	45	use	use	NOUN
dhrp-29	5	46	in	in	ADP
dhrp-29	5	47	people	people	NOUN
dhrp-29	5	48	16	16	NUM
dhrp-29	5	49	years	year	NOUN
dhrp-29	5	50	of	of	ADP
dhrp-29	5	51	age	age	NOUN
dhrp-29	5	52	or	or	CCONJ
dhrp-29	5	53	older	old	ADJ
dhrp-29	5	54	(	(	PUNCT
dhrp-29	5	55	2	2	NUM
dhrp-29	5	56	)	)	PUNCT
dhrp-29	5	57	.	.	PUNCT
dhrp-29	6	1	with	with	ADP
dhrp-29	6	2	well	well	ADV
dhrp-29	6	3	over	over	ADP
dhrp-29	6	4	21	21	NUM
dhrp-29	6	5	months	month	NOUN
dhrp-29	6	6	into	into	ADP
dhrp-29	6	7	this	this	DET
dhrp-29	6	8	pandemic	pandemic	NOUN
dhrp-29	6	9	,	,	PUNCT
dhrp-29	6	10	we	we	PRON
dhrp-29	6	11	still	still	ADV
dhrp-29	6	12	do	do	AUX
dhrp-29	6	13	not	not	PART
dhrp-29	6	14	have	have	VERB
dhrp-29	6	15	any	any	DET
dhrp-29	6	16	treatment	treatment	NOUN
dhrp-29	6	17	that	that	PRON
dhrp-29	6	18	has	have	AUX
dhrp-29	6	19	received	receive	VERB
dhrp-29	6	20	full	full	ADJ
dhrp-29	6	21	fda	fda	PROPN
dhrp-29	6	22	approval	approval	NOUN
dhrp-29	6	23	for	for	ADP
dhrp-29	6	24	covid-19	covid-19	PROPN
dhrp-29	6	25	.	.	PUNCT
dhrp-29	7	1	numerous	numerous	ADJ
dhrp-29	7	2	agents	agent	NOUN
dhrp-29	7	3	have	have	AUX
dhrp-29	7	4	been	be	AUX
dhrp-29	7	5	approved	approve	VERB
dhrp-29	7	6	under	under	ADP
dhrp-29	7	7	eua	eua	PROPN
dhrp-29	7	8	for	for	ADP
dhrp-29	7	9	the	the	DET
dhrp-29	7	10	treatment	treatment	NOUN
dhrp-29	7	11	of	of	ADP
dhrp-29	7	12	sars	sar	NOUN
dhrp-29	7	13	-	-	PUNCT
dhrp-29	7	14	cov-2	cov-2	NOUN
dhrp-29	7	15	infection	infection	NOUN
dhrp-29	7	16	in	in	ADP
dhrp-29	7	17	high	high	ADJ
dhrp-29	7	18	-	-	PUNCT
dhrp-29	7	19	risk	risk	NOUN
dhrp-29	7	20	patients	patient	NOUN
dhrp-29	7	21	and	and	CCONJ
dhrp-29	7	22	several	several	ADJ
dhrp-29	7	23	clinical	clinical	ADJ
dhrp-29	7	24	trials	trial	NOUN
dhrp-29	7	25	are	be	AUX
dhrp-29	7	26	currently	currently	ADV
dhrp-29	7	27	underway	underway	ADJ
dhrp-29	7	28	to	to	PART
dhrp-29	7	29	discover	discover	VERB
dhrp-29	7	30	the	the	DET
dhrp-29	7	31	elusive	elusive	ADJ
dhrp-29	7	32	drug	drug	NOUN
dhrp-29	7	33	for	for	ADP
dhrp-29	7	34	this	this	DET
dhrp-29	7	35	purpose	purpose	NOUN
dhrp-29	7	36	.	.	PUNCT
dhrp-29	8	1	the	the	DET
dhrp-29	8	2	only	only	ADJ
dhrp-29	8	3	agents	agent	NOUN
dhrp-29	8	4	currently	currently	ADV
dhrp-29	8	5	approved	approve	VERB
dhrp-29	8	6	for	for	ADP
dhrp-29	8	7	outpatient	outpatient	NOUN
dhrp-29	8	8	use	use	NOUN
dhrp-29	8	9	under	under	ADP
dhrp-29	8	10	eua	eua	PROPN
dhrp-29	8	11	for	for	ADP
dhrp-29	8	12	the	the	DET
dhrp-29	8	13	treatment	treatment	NOUN
dhrp-29	8	14	of	of	ADP
dhrp-29	8	15	mild	mild	ADJ
dhrp-29	8	16	-	-	PUNCT
dhrp-29	8	17	moderate	moderate	ADJ
dhrp-29	8	18	sarscov-2	sarscov-2	NUM
dhrp-29	8	19	infection	infection	NOUN
dhrp-29	8	20	are	be	AUX
dhrp-29	8	21	the	the	DET
dhrp-29	8	22	three	three	NUM
dhrp-29	8	23	monoclonal	monoclonal	NOUN
dhrp-29	8	24	antibody	antibody	NOUN
dhrp-29	8	25	cocktails	cocktail	NOUN
dhrp-29	8	26	that	that	PRON
dhrp-29	8	27	require	require	VERB
dhrp-29	8	28	intravenous	intravenous	ADJ
dhrp-29	8	29	infusion	infusion	NOUN
dhrp-29	8	30	thus	thus	ADV
dhrp-29	8	31	limiting	limit	VERB
dhrp-29	8	32	their	their	PRON
dhrp-29	8	33	utility	utility	NOUN
dhrp-29	8	34	on	on	ADP
dhrp-29	8	35	a	a	DET
dhrp-29	8	36	widespread	widespread	ADJ
dhrp-29	8	37	basis	basis	NOUN
dhrp-29	8	38	(	(	PUNCT
dhrp-29	8	39	3	3	NUM
dhrp-29	8	40	)	)	PUNCT
dhrp-29	8	41	.	.	PUNCT
dhrp-29	9	1	an	an	DET
dhrp-29	9	2	ideal	ideal	ADJ
dhrp-29	9	3	drug	drug	NOUN
dhrp-29	9	4	for	for	ADP
dhrp-29	9	5	the	the	DET
dhrp-29	9	6	treatment	treatment	NOUN
dhrp-29	9	7	of	of	ADP
dhrp-29	9	8	covid-19	covid-19	PROPN
dhrp-29	9	9	would	would	AUX
dhrp-29	9	10	be	be	AUX
dhrp-29	9	11	an	an	DET
dhrp-29	9	12	oral	oral	ADJ
dhrp-29	9	13	medication	medication	NOUN
dhrp-29	9	14	that	that	PRON
dhrp-29	9	15	could	could	AUX
dhrp-29	9	16	be	be	AUX
dhrp-29	9	17	administered	administer	VERB
dhrp-29	9	18	out	out	ADP
dhrp-29	9	19	-	-	PUNCT
dhrp-29	9	20	of	of	ADP
dhrp-29	9	21	-	-	PUNCT
dhrp-29	9	22	hospitals	hospital	NOUN
dhrp-29	9	23	to	to	ADP
dhrp-29	9	24	patients	patient	NOUN
dhrp-29	9	25	with	with	ADP
dhrp-29	9	26	mild	mild	ADJ
dhrp-29	9	27	-	-	PUNCT
dhrp-29	9	28	moderate	moderate	ADJ
dhrp-29	9	29	disease	disease	NOUN
dhrp-29	9	30	.	.	PUNCT
dhrp-29	10	1	the	the	DET
dhrp-29	10	2	full	full	ADJ
dhrp-29	10	3	genome	genome	NOUN
dhrp-29	10	4	of	of	ADP
dhrp-29	10	5	sarscov-2	sarscov-2	NUM
dhrp-29	10	6	has	have	AUX
dhrp-29	10	7	been	be	AUX
dhrp-29	10	8	identified	identify	VERB
dhrp-29	10	9	and	and	CCONJ
dhrp-29	10	10	researchers	researcher	NOUN
dhrp-29	10	11	have	have	AUX
dhrp-29	10	12	also	also	ADV
dhrp-29	10	13	used	use	VERB
dhrp-29	10	14	advanced	advanced	ADJ
dhrp-29	10	15	microscopy	microscopy	NOUN
dhrp-29	10	16	techniques	technique	NOUN
dhrp-29	10	17	to	to	PART
dhrp-29	10	18	map	map	VERB
dhrp-29	10	19	the	the	DET
dhrp-29	10	20	3d	3d	NUM
dhrp-29	10	21	structure	structure	NOUN
dhrp-29	10	22	of	of	ADP
dhrp-29	10	23	the	the	DET
dhrp-29	10	24	virus	virus	NOUN
dhrp-29	10	25	proteins	protein	NOUN
dhrp-29	10	26	in	in	ADP
dhrp-29	10	27	detail	detail	NOUN
dhrp-29	10	28	(	(	PUNCT
dhrp-29	10	29	4	4	NUM
dhrp-29	10	30	)	)	PUNCT
dhrp-29	10	31	.	.	PUNCT
dhrp-29	11	1	together	together	ADV
dhrp-29	11	2	,	,	PUNCT
dhrp-29	11	3	this	this	DET
dhrp-29	11	4	information	information	NOUN
dhrp-29	11	5	has	have	AUX
dhrp-29	11	6	propelled	propel	VERB
dhrp-29	11	7	the	the	DET
dhrp-29	11	8	search	search	NOUN
dhrp-29	11	9	for	for	ADP
dhrp-29	11	10	new	new	ADJ
dhrp-29	11	11	drugs	drug	NOUN
dhrp-29	11	12	to	to	PART
dhrp-29	11	13	treat	treat	VERB
dhrp-29	11	14	sars	sar	NOUN
dhrp-29	11	15	-	-	PUNCT
dhrp-29	11	16	cov-2	cov-2	PART
dhrp-29	11	17	infection	infection	NOUN
dhrp-29	11	18	that	that	PRON
dhrp-29	11	19	specifically	specifically	ADV
dhrp-29	11	20	target	target	VERB
dhrp-29	11	21	its	its	PRON
dhrp-29	11	22	structure	structure	NOUN
dhrp-29	11	23	and	and	CCONJ
dhrp-29	11	24	functions	function	NOUN
dhrp-29	11	25	.	.	PUNCT
dhrp-29	12	1	in	in	ADP
dhrp-29	12	2	a	a	DET
dhrp-29	12	3	recent	recent	ADJ
dhrp-29	12	4	non	non	ADJ
dhrp-29	12	5	-	-	ADJ
dhrp-29	12	6	peer	peer	ADJ
dhrp-29	12	7	reviewed	review	VERB
dhrp-29	12	8	article	article	NOUN
dhrp-29	12	9	,	,	PUNCT
dhrp-29	12	10	fischer	fischer	PROPN
dhrp-29	12	11	,	,	PUNCT
dhrp-29	12	12	et.al	et.al	PROPN
dhrp-29	12	13	.	.	PROPN
dhrp-29	12	14	,	,	PUNCT
dhrp-29	12	15	have	have	AUX
dhrp-29	12	16	claimed	claim	VERB
dhrp-29	12	17	that	that	SCONJ
dhrp-29	12	18	molnupiravir	molnupiravir	PROPN
dhrp-29	12	19	–	–	PUNCT
dhrp-29	12	20	an	an	DET
dhrp-29	12	21	experimental	experimental	ADJ
dhrp-29	12	22	anti	anti	ADJ
dhrp-29	12	23	-	-	ADJ
dhrp-29	12	24	viral	viral	ADJ
dhrp-29	12	25	agent	agent	NOUN
dhrp-29	12	26	when	when	SCONJ
dhrp-29	12	27	administered	administer	VERB
dhrp-29	12	28	orally	orally	ADV
dhrp-29	12	29	in	in	ADP
dhrp-29	12	30	patients	patient	NOUN
dhrp-29	12	31	with	with	ADP
dhrp-29	12	32	mild	mild	ADJ
dhrp-29	12	33	to	to	ADP
dhrp-29	12	34	moderated	moderated	ADJ
dhrp-29	12	35	sars	sars	PROPN
dhrp-29	12	36	-	-	PUNCT
dhrp-29	12	37	cov-2	cov-2	PART
dhrp-29	12	38	infection	infection	NOUN
dhrp-29	12	39	reduced	reduce	VERB
dhrp-29	12	40	the	the	DET
dhrp-29	12	41	risk	risk	NOUN
dhrp-29	12	42	of	of	ADP
dhrp-29	12	43	hospitalization	hospitalization	NOUN
dhrp-29	12	44	or	or	CCONJ
dhrp-29	12	45	death	death	NOUN
dhrp-29	12	46	by	by	ADP
dhrp-29	12	47	about	about	ADV
dhrp-29	12	48	50	50	NUM
dhrp-29	12	49	%	%	NOUN
dhrp-29	12	50	as	as	ADP
dhrp-29	12	51	compared	compare	VERB
dhrp-29	12	52	to	to	ADP
dhrp-29	12	53	the	the	DET
dhrp-29	12	54	placebo	placebo	NOUN
dhrp-29	12	55	(	(	PUNCT
dhrp-29	12	56	5	5	NUM
dhrp-29	12	57	)	)	PUNCT
dhrp-29	12	58	.	.	PUNCT
dhrp-29	13	1	these	these	DET
dhrp-29	13	2	observations	observation	NOUN
dhrp-29	13	3	prompted	prompt	VERB
dhrp-29	13	4	a	a	DET
dhrp-29	13	5	recent	recent	ADJ
dhrp-29	13	6	news	news	NOUN
dhrp-29	13	7	release	release	NOUN
dhrp-29	13	8	by	by	ADP
dhrp-29	13	9	merck	merck	PROPN
dhrp-29	13	10	(	(	PUNCT
dhrp-29	13	11	who	who	PRON
dhrp-29	13	12	developed	develop	VERB
dhrp-29	13	13	molnupiravir	molnupiravir	PROPN
dhrp-29	13	14	in	in	ADP
dhrp-29	13	15	partnership	partnership	NOUN
dhrp-29	13	16	with	with	ADP
dhrp-29	13	17	ridgeback	ridgeback	NOUN
dhrp-29	13	18	biotherapeutics	biotherapeutic	NOUN
dhrp-29	13	19	)	)	PUNCT
dhrp-29	13	20	indicating	indicate	VERB
dhrp-29	13	21	that	that	SCONJ
dhrp-29	13	22	they	they	PRON
dhrp-29	13	23	will	will	AUX
dhrp-29	13	24	be	be	AUX
dhrp-29	13	25	submitting	submit	VERB
dhrp-29	13	26	an	an	DET
dhrp-29	13	27	investigational	investigational	ADJ
dhrp-29	13	28	new	new	ADJ
dhrp-29	13	29	drug	drug	NOUN
dhrp-29	13	30	application	application	NOUN
dhrp-29	13	31	to	to	ADP
dhrp-29	13	32	the	the	DET
dhrp-29	13	33	fda	fda	PROPN
dhrp-29	13	34	seeking	seek	VERB
dhrp-29	13	35	eua	eua	PROPN
dhrp-29	13	36	for	for	ADP
dhrp-29	13	37	oral	oral	ADJ
dhrp-29	13	38	treatment	treatment	NOUN
dhrp-29	13	39	of	of	ADP
dhrp-29	13	40	patients	patient	NOUN
dhrp-29	13	41	with	with	ADP
dhrp-29	13	42	mild	mild	ADJ
dhrp-29	13	43	-	-	PUNCT
dhrp-29	13	44	moderate	moderate	ADJ
dhrp-29	13	45	covid19	covid19	NOUN
dhrp-29	13	46	(	(	PUNCT
dhrp-29	13	47	6	6	NUM
dhrp-29	13	48	)	)	PUNCT
dhrp-29	13	49	.	.	PUNCT
dhrp-29	14	1	molnupiravir	molnupiravir	PROPN
dhrp-29	14	2	was	be	AUX
dhrp-29	14	3	originally	originally	ADV
dhrp-29	14	4	developed	develop	VERB
dhrp-29	14	5	by	by	ADP
dhrp-29	14	6	drug	drug	NOUN
dhrp-29	14	7	innovations	innovation	NOUN
dhrp-29	14	8	at	at	ADP
dhrp-29	14	9	emory	emory	PROPN
dhrp-29	14	10	university	university	PROPN
dhrp-29	14	11	to	to	PART
dhrp-29	14	12	treat	treat	VERB
dhrp-29	14	13	influenza	influenza	NOUN
dhrp-29	14	14	(	(	PUNCT
dhrp-29	14	15	7	7	NUM
dhrp-29	14	16	)	)	PUNCT
dhrp-29	14	17	.	.	PUNCT
dhrp-29	15	1	it	it	PRON
dhrp-29	15	2	is	be	AUX
dhrp-29	15	3	a	a	DET
dhrp-29	15	4	pro	pro	ADJ
dhrp-29	15	5	-	-	ADJ
dhrp-29	15	6	drug	drug	NOUN
dhrp-29	15	7	that	that	PRON
dhrp-29	15	8	is	be	AUX
dhrp-29	15	9	metabolized	metabolize	VERB
dhrp-29	15	10	into	into	ADP
dhrp-29	15	11	a	a	DET
dhrp-29	15	12	ribonucleoside	ribonucleoside	NOUN
dhrp-29	15	13	(	(	PUNCT
dhrp-29	15	14	rna	rna	NOUN
dhrp-29	15	15	)	)	PUNCT
dhrp-29	15	16	analog	analog	NOUN
dhrp-29	15	17	that	that	PRON
dhrp-29	15	18	resembles	resemble	VERB
dhrp-29	15	19	cytidine	cytidine	NOUN
dhrp-29	15	20	–	–	PUNCT
dhrp-29	15	21	a	a	DET
dhrp-29	15	22	critical	critical	ADJ
dhrp-29	15	23	component	component	NOUN
dhrp-29	15	24	of	of	ADP
dhrp-29	15	25	rna	rna	PROPN
dhrp-29	15	26	.	.	PUNCT
dhrp-29	16	1	molnupiravir	molnupiravir	PROPN
dhrp-29	16	2	’s	’s	PART
dhrp-29	16	3	anti	anti	ADJ
dhrp-29	16	4	-	-	ADJ
dhrp-29	16	5	viral	viral	ADJ
dhrp-29	16	6	activity	activity	NOUN
dhrp-29	16	7	is	be	AUX
dhrp-29	16	8	exerted	exert	VERB
dhrp-29	16	9	by	by	ADP
dhrp-29	16	10	a	a	DET
dhrp-29	16	11	process	process	NOUN
dhrp-29	16	12	known	know	VERB
dhrp-29	16	13	as	as	ADP
dhrp-29	16	14	lethal	lethal	ADJ
dhrp-29	16	15	mutagenesis	mutagenesis	NOUN
dhrp-29	16	16	or	or	CCONJ
dhrp-29	16	17	viral	viral	ADJ
dhrp-29	16	18	error	error	NOUN
dhrp-29	16	19	catastrophe	catastrophe	NOUN
dhrp-29	16	20	.	.	PUNCT
dhrp-29	17	1	essentially	essentially	ADV
dhrp-29	17	2	,	,	PUNCT
dhrp-29	17	3	during	during	ADP
dhrp-29	17	4	replication	replication	NOUN
dhrp-29	17	5	,	,	PUNCT
dhrp-29	17	6	the	the	DET
dhrp-29	17	7	viral	viral	ADJ
dhrp-29	17	8	rna	rna	NOUN
dhrp-29	17	9	incorporates	incorporate	VERB
dhrp-29	17	10	molnupiravir	molnupiravir	PROPN
dhrp-29	17	11	which	which	PRON
dhrp-29	17	12	leads	lead	VERB
dhrp-29	17	13	to	to	ADP
dhrp-29	17	14	downstream	downstream	ADJ
dhrp-29	17	15	mutations	mutation	NOUN
dhrp-29	17	16	resulting	result	VERB
dhrp-29	17	17	in	in	ADP
dhrp-29	17	18	catastrophic	catastrophic	ADJ
dhrp-29	17	19	errors	error	NOUN
dhrp-29	17	20	that	that	PRON
dhrp-29	17	21	adversely	adversely	ADV
dhrp-29	17	22	impact	impact	VERB
dhrp-29	17	23	the	the	DET
dhrp-29	17	24	survival	survival	NOUN
dhrp-29	17	25	of	of	ADP
dhrp-29	17	26	the	the	DET
dhrp-29	17	27	virus	virus	NOUN
dhrp-29	17	28	.	.	PUNCT
dhrp-29	18	1	the	the	DET
dhrp-29	18	2	non	non	ADJ
dhrp-29	18	3	-	-	ADJ
dhrp-29	18	4	peer	peer	ADJ
dhrp-29	18	5	reviewed	review	VERB
dhrp-29	18	6	unpublished	unpublished	ADJ
dhrp-29	18	7	interim	interim	ADJ
dhrp-29	18	8	data	datum	NOUN
dhrp-29	18	9	that	that	PRON
dhrp-29	18	10	merck	merck	PROPN
dhrp-29	18	11	is	be	AUX
dhrp-29	18	12	planning	plan	VERB
dhrp-29	18	13	to	to	PART
dhrp-29	18	14	use	use	VERB
dhrp-29	18	15	to	to	PART
dhrp-29	18	16	obtain	obtain	VERB
dhrp-29	18	17	an	an	DET
dhrp-29	18	18	eua	eua	PROPN
dhrp-29	18	19	emanates	emanate	VERB
dhrp-29	18	20	from	from	ADP
dhrp-29	18	21	interim	interim	ADJ
dhrp-29	18	22	analysis	analysis	NOUN
dhrp-29	18	23	of	of	ADP
dhrp-29	18	24	a	a	DET
dhrp-29	18	25	phase	phase	NOUN
dhrp-29	18	26	3	3	NUM
dhrp-29	18	27	trial	trial	NOUN
dhrp-29	18	28	(	(	PUNCT
dhrp-29	18	29	move	move	NOUN
dhrp-29	18	30	-	-	PUNCT
dhrp-29	18	31	out	out	NOUN
dhrp-29	18	32	)	)	PUNCT
dhrp-29	18	33	which	which	PRON
dhrp-29	18	34	was	be	AUX
dhrp-29	18	35	a	a	DET
dhrp-29	18	36	randomized	randomized	ADJ
dhrp-29	18	37	,	,	PUNCT
dhrp-29	18	38	controlled	control	VERB
dhrp-29	18	39	,	,	PUNCT
dhrp-29	18	40	double	double	ADJ
dhrp-29	18	41	-	-	PUNCT
dhrp-29	18	42	blinded	blind	VERB
dhrp-29	18	43	assessment	assessment	NOUN
dhrp-29	18	44	of	of	ADP
dhrp-29	18	45	molnupiravir	molnupiravir	PROPN
dhrp-29	18	46	versus	versus	ADP
dhrp-29	18	47	placebo	placebo	NOUN
dhrp-29	18	48	in	in	ADP
dhrp-29	18	49	non	non	ADJ
dhrp-29	18	50	-	-	ADJ
dhrp-29	18	51	hospitalized	hospitalize	VERB
dhrp-29	18	52	adults	adult	NOUN
dhrp-29	18	53	with	with	ADP
dhrp-29	18	54	mild	mild	ADJ
dhrp-29	18	55	to	to	PART
dhrp-29	18	56	moderate	moderate	VERB
dhrp-29	18	57	covid-19	covid-19	PROPN
dhrp-29	18	58	with	with	ADP
dhrp-29	18	59	symptom	symptom	NOUN
dhrp-29	18	60	onset	onset	NOUN
dhrp-29	18	61	within	within	ADP
dhrp-29	18	62	5	5	NUM
dhrp-29	18	63	days	day	NOUN
dhrp-29	18	64	prior	prior	ADV
dhrp-29	18	65	to	to	ADP
dhrp-29	18	66	their	their	PRON
dhrp-29	18	67	randomization	randomization	NOUN
dhrp-29	18	68	.	.	PUNCT
dhrp-29	19	1	it	it	PRON
dhrp-29	19	2	is	be	AUX
dhrp-29	19	3	important	important	ADJ
dhrp-29	19	4	to	to	PART
dhrp-29	19	5	note	note	VERB
dhrp-29	19	6	that	that	SCONJ
dhrp-29	19	7	the	the	DET
dhrp-29	19	8	eligible	eligible	ADJ
dhrp-29	19	9	trial	trial	NOUN
dhrp-29	19	10	participants	participant	NOUN
dhrp-29	19	11	had	have	VERB
dhrp-29	19	12	≥1	≥1	NOUN
dhrp-29	19	13	risk	risk	NOUN
dhrp-29	19	14	factor	factor	NOUN
dhrp-29	19	15	(	(	PUNCT
dhrp-29	19	16	such	such	ADJ
dhrp-29	19	17	as	as	ADP
dhrp-29	19	18	obesity	obesity	NOUN
dhrp-29	19	19	,	,	PUNCT
dhrp-29	19	20	diabetes	diabetes	NOUN
dhrp-29	19	21	,	,	PUNCT
dhrp-29	19	22	old	old	ADJ
dhrp-29	19	23	age	age	NOUN
dhrp-29	19	24	,	,	PUNCT
dhrp-29	19	25	etc	etc	X
dhrp-29	19	26	.	.	X
dhrp-29	19	27	)	)	PUNCT
dhrp-29	20	1	that	that	PRON
dhrp-29	20	2	are	be	AUX
dhrp-29	20	3	associated	associate	VERB
dhrp-29	20	4	with	with	ADP
dhrp-29	20	5	poor	poor	ADJ
dhrp-29	20	6	covid-19	covid-19	PROPN
dhrp-29	20	7	outcomes	outcome	NOUN
dhrp-29	20	8	.	.	PUNCT
dhrp-29	21	1	the	the	DET
dhrp-29	21	2	primary	primary	ADJ
dhrp-29	21	3	outcome	outcome	NOUN
dhrp-29	21	4	of	of	ADP
dhrp-29	21	5	this	this	DET
dhrp-29	21	6	trial	trial	NOUN
dhrp-29	21	7	was	be	AUX
dhrp-29	21	8	to	to	PART
dhrp-29	21	9	determine	determine	VERB
dhrp-29	21	10	the	the	DET
dhrp-29	21	11	efficacy	efficacy	NOUN
dhrp-29	21	12	of	of	ADP
dhrp-29	21	13	molnupiravir	molnupiravir	PROPN
dhrp-29	21	14	by	by	ADP
dhrp-29	21	15	evaluating	evaluate	VERB
dhrp-29	21	16	the	the	DET
dhrp-29	21	17	percentage	percentage	NOUN
dhrp-29	21	18	of	of	ADP
dhrp-29	21	19	participants	participant	NOUN
dhrp-29	21	20	who	who	PRON
dhrp-29	21	21	are	be	AUX
dhrp-29	21	22	hospitalized	hospitalize	VERB
dhrp-29	21	23	and/or	and/or	CCONJ
dhrp-29	21	24	who	who	PRON
dhrp-29	21	25	have	have	AUX
dhrp-29	21	26	died	die	VERB
dhrp-29	21	27	through	through	ADP
dhrp-29	21	28	29	29	NUM
dhrp-29	21	29	days	day	NOUN
dhrp-29	21	30	postrandomization	postrandomization	NOUN
dhrp-29	21	31	.	.	PUNCT
dhrp-29	22	1	dhrp	dhrp	ADJ
dhrp-29	22	2	,	,	PUNCT
dhrp-29	22	3	2021	2021	NUM
dhrp-29	22	4	,	,	PUNCT
dhrp-29	22	5	vol	vol	NOUN
dhrp-29	22	6	.	.	NOUN
dhrp-29	22	7	1	1	NUM
dhrp-29	22	8	(	(	PUNCT
dhrp-29	22	9	s4	s4	PROPN
dhrp-29	22	10	)	)	PUNCT
dhrp-29	22	11	20	20	NUM
dhrp-29	22	12	-	-	SYM
dhrp-29	22	13	21	21	NUM
dhrp-29	22	14	editorial	editorial	NOUN
dhrp-29	22	15	http://dhrproceedings.org	http://dhrproceedings.org	PROPN
dhrp-29	22	16	21	21	NUM
dhrp-29	22	17	©	©	PROPN
dhrp-29	22	18	dhr	dhr	PROPN
dhrp-29	22	19	health	health	PROPN
dhrp-29	22	20	institute	institute	PROPN
dhrp-29	22	21	for	for	ADP
dhrp-29	22	22	research	research	NOUN
dhrp-29	22	23	and	and	CCONJ
dhrp-29	22	24	development	development	NOUN
dhrp-29	22	25	the	the	DET
dhrp-29	22	26	key	key	ADJ
dhrp-29	22	27	observations	observation	NOUN
dhrp-29	22	28	of	of	ADP
dhrp-29	22	29	an	an	DET
dhrp-29	22	30	interim	interim	ADJ
dhrp-29	22	31	analysis	analysis	NOUN
dhrp-29	22	32	of	of	ADP
dhrp-29	22	33	this	this	DET
dhrp-29	22	34	phase	phase	NOUN
dhrp-29	22	35	3	3	NUM
dhrp-29	22	36	(	(	PUNCT
dhrp-29	22	37	move	move	NOUN
dhrp-29	22	38	-	-	PUNCT
dhrp-29	22	39	out	out	NOUN
dhrp-29	22	40	)	)	PUNCT
dhrp-29	22	41	study	study	NOUN
dhrp-29	22	42	were	be	AUX
dhrp-29	22	43	:	:	PUNCT
dhrp-29	22	44	•	•	NUM
dhrp-29	22	45	molnupiravir	molnupiravir	PROPN
dhrp-29	22	46	reduced	reduce	VERB
dhrp-29	22	47	the	the	DET
dhrp-29	22	48	patient	patient	NOUN
dhrp-29	22	49	’s	’s	PART
dhrp-29	22	50	risk	risk	NOUN
dhrp-29	22	51	of	of	ADP
dhrp-29	22	52	covid-19	covid-19	PROPN
dhrp-29	22	53	hospitalization	hospitalization	NOUN
dhrp-29	22	54	or	or	CCONJ
dhrp-29	22	55	death	death	NOUN
dhrp-29	22	56	by	by	ADP
dhrp-29	22	57	approximately	approximately	ADV
dhrp-29	22	58	50	50	NUM
dhrp-29	22	59	%	%	NOUN
dhrp-29	22	60	:	:	PUNCT
dhrp-29	23	1	o	o	X
dhrp-29	23	2	only	only	ADV
dhrp-29	23	3	28	28	NUM
dhrp-29	23	4	(	(	PUNCT
dhrp-29	23	5	7.3	7.3	NUM
dhrp-29	23	6	%	%	NOUN
dhrp-29	23	7	)	)	PUNCT
dhrp-29	23	8	patients	patient	NOUN
dhrp-29	23	9	who	who	PRON
dhrp-29	23	10	received	receive	VERB
dhrp-29	23	11	molnupiravir	molnupiravir	PROPN
dhrp-29	23	12	were	be	AUX
dhrp-29	23	13	hospitalized	hospitalize	VERB
dhrp-29	23	14	,	,	PUNCT
dhrp-29	23	15	versus	versus	ADP
dhrp-29	23	16	53	53	NUM
dhrp-29	23	17	(	(	PUNCT
dhrp-29	23	18	14.1	14.1	NUM
dhrp-29	23	19	%	%	NOUN
dhrp-29	23	20	)	)	PUNCT
dhrp-29	23	21	patients	patient	NOUN
dhrp-29	23	22	who	who	PRON
dhrp-29	23	23	were	be	AUX
dhrp-29	23	24	administered	administer	VERB
dhrp-29	23	25	placebo	placebo	NOUN
dhrp-29	23	26	o	o	NOUN
dhrp-29	23	27	as	as	SCONJ
dhrp-29	23	28	compared	compare	VERB
dhrp-29	23	29	to	to	ADP
dhrp-29	23	30	eight	eight	NUM
dhrp-29	23	31	(	(	PUNCT
dhrp-29	23	32	8)	8)	NUM
dhrp-29	23	33	patients	patient	NOUN
dhrp-29	23	34	in	in	ADP
dhrp-29	23	35	the	the	DET
dhrp-29	23	36	placebo	placebo	NOUN
dhrp-29	23	37	arm	arm	NOUN
dhrp-29	23	38	,	,	PUNCT
dhrp-29	23	39	no	no	DET
dhrp-29	23	40	patients	patient	NOUN
dhrp-29	23	41	who	who	PRON
dhrp-29	23	42	received	receive	VERB
dhrp-29	23	43	molnupiravir	molnupiravir	PROPN
dhrp-29	23	44	died	die	VERB
dhrp-29	23	45	through	through	ADP
dhrp-29	23	46	29	29	NUM
dhrp-29	23	47	days	day	NOUN
dhrp-29	23	48	post	post	ADJ
dhrp-29	23	49	-	-	NOUN
dhrp-29	23	50	randomization	randomization	NOUN
dhrp-29	23	51	•	•	NOUN
dhrp-29	23	52	molnupiravir	molnupiravir	PROPN
dhrp-29	23	53	was	be	AUX
dhrp-29	23	54	consistently	consistently	ADV
dhrp-29	23	55	effective	effective	ADJ
dhrp-29	23	56	against	against	ADP
dhrp-29	23	57	delta	delta	NOUN
dhrp-29	23	58	,	,	PUNCT
dhrp-29	23	59	gamma	gamma	NOUN
dhrp-29	23	60	,	,	PUNCT
dhrp-29	23	61	and	and	CCONJ
dhrp-29	23	62	mu	mu	PROPN
dhrp-29	23	63	sars	sars	PROPN
dhrp-29	23	64	-	-	PUNCT
dhrp-29	23	65	cov2	cov2	PROPN
dhrp-29	23	66	variants	variant	NOUN
dhrp-29	23	67	•	•	SCONJ
dhrp-29	23	68	adverse	adverse	ADJ
dhrp-29	23	69	events	event	NOUN
dhrp-29	23	70	occurred	occur	VERB
dhrp-29	23	71	in	in	ADP
dhrp-29	23	72	35	35	NUM
dhrp-29	23	73	%	%	NOUN
dhrp-29	23	74	and	and	CCONJ
dhrp-29	23	75	40	40	NUM
dhrp-29	23	76	%	%	NOUN
dhrp-29	23	77	of	of	ADP
dhrp-29	23	78	patients	patient	NOUN
dhrp-29	23	79	treated	treat	VERB
dhrp-29	23	80	with	with	ADP
dhrp-29	23	81	molnupiravir	molnupiravir	PROPN
dhrp-29	23	82	versus	versus	ADP
dhrp-29	23	83	placebo	placebo	NOUN
dhrp-29	23	84	,	,	PUNCT
dhrp-29	23	85	respectively	respectively	ADV
dhrp-29	23	86	,	,	PUNCT
dhrp-29	23	87	however	however	ADV
dhrp-29	23	88	,	,	PUNCT
dhrp-29	23	89	trial	trial	NOUN
dhrp-29	23	90	discontinuation	discontinuation	NOUN
dhrp-29	23	91	due	due	ADP
dhrp-29	23	92	to	to	ADP
dhrp-29	23	93	adverse	adverse	ADJ
dhrp-29	23	94	event	event	NOUN
dhrp-29	23	95	was	be	AUX
dhrp-29	23	96	lower	low	ADJ
dhrp-29	23	97	(	(	PUNCT
dhrp-29	23	98	1.3	1.3	NUM
dhrp-29	23	99	%	%	NOUN
dhrp-29	23	100	)	)	PUNCT
dhrp-29	23	101	in	in	ADP
dhrp-29	23	102	the	the	DET
dhrp-29	23	103	treatment	treatment	NOUN
dhrp-29	23	104	group	group	NOUN
dhrp-29	23	105	as	as	SCONJ
dhrp-29	23	106	compared	compare	VERB
dhrp-29	23	107	to	to	ADP
dhrp-29	23	108	the	the	DET
dhrp-29	23	109	placebo	placebo	NOUN
dhrp-29	23	110	group	group	NOUN
dhrp-29	23	111	(	(	PUNCT
dhrp-29	23	112	3.4	3.4	NUM
dhrp-29	23	113	%	%	NOUN
dhrp-29	23	114	)	)	PUNCT
dhrp-29	23	115	with	with	ADP
dhrp-29	23	116	the	the	DET
dhrp-29	23	117	human	human	ADJ
dhrp-29	23	118	death	death	NOUN
dhrp-29	23	119	toll	toll	NOUN
dhrp-29	23	120	in	in	ADP
dhrp-29	23	121	the	the	DET
dhrp-29	23	122	us	we	PRON
dhrp-29	23	123	due	due	ADP
dhrp-29	23	124	to	to	ADP
dhrp-29	23	125	covid19	covid19	NOUN
dhrp-29	23	126	now	now	ADV
dhrp-29	23	127	outstripping	outstrip	VERB
dhrp-29	23	128	that	that	PRON
dhrp-29	23	129	during	during	ADP
dhrp-29	23	130	the	the	DET
dhrp-29	23	131	1918	1918	NUM
dhrp-29	23	132	influenza	influenza	NOUN
dhrp-29	23	133	pandemic	pandemic	ADJ
dhrp-29	23	134	,	,	PUNCT
dhrp-29	23	135	the	the	DET
dhrp-29	23	136	quest	quest	NOUN
dhrp-29	23	137	to	to	PART
dhrp-29	23	138	discover	discover	VERB
dhrp-29	23	139	an	an	DET
dhrp-29	23	140	oral	oral	ADJ
dhrp-29	23	141	drug	drug	NOUN
dhrp-29	23	142	that	that	PRON
dhrp-29	23	143	is	be	AUX
dhrp-29	23	144	approved	approve	VERB
dhrp-29	23	145	by	by	ADP
dhrp-29	23	146	the	the	DET
dhrp-29	23	147	fda	fda	PROPN
dhrp-29	23	148	to	to	PART
dhrp-29	23	149	treat	treat	VERB
dhrp-29	23	150	patients	patient	NOUN
dhrp-29	23	151	with	with	ADP
dhrp-29	23	152	mildmoderate	mildmoderate	NOUN
dhrp-29	23	153	sars	sar	NOUN
dhrp-29	23	154	-	-	PUNCT
dhrp-29	23	155	cov-2	cov-2	PART
dhrp-29	23	156	infection	infection	NOUN
dhrp-29	23	157	has	have	AUX
dhrp-29	23	158	achieved	achieve	VERB
dhrp-29	23	159	the	the	DET
dhrp-29	23	160	revered	revere	VERB
dhrp-29	23	161	status	status	NOUN
dhrp-29	23	162	of	of	ADP
dhrp-29	23	163	the	the	DET
dhrp-29	23	164	holy	holy	ADJ
dhrp-29	23	165	grail	grail	NOUN
dhrp-29	23	166	in	in	ADP
dhrp-29	23	167	the	the	DET
dhrp-29	23	168	field	field	NOUN
dhrp-29	23	169	of	of	ADP
dhrp-29	23	170	medicine	medicine	NOUN
dhrp-29	23	171	and	and	CCONJ
dhrp-29	23	172	public	public	ADJ
dhrp-29	23	173	health	health	NOUN
dhrp-29	23	174	.	.	PUNCT
dhrp-29	24	1	interim	interim	ADJ
dhrp-29	24	2	data	datum	NOUN
dhrp-29	24	3	analysis	analysis	NOUN
dhrp-29	24	4	suggests	suggest	VERB
dhrp-29	24	5	that	that	SCONJ
dhrp-29	24	6	molnupiravir	molnupiravir	PROPN
dhrp-29	24	7	has	have	VERB
dhrp-29	24	8	the	the	DET
dhrp-29	24	9	potential	potential	NOUN
dhrp-29	24	10	to	to	PART
dhrp-29	24	11	be	be	AUX
dhrp-29	24	12	a	a	DET
dhrp-29	24	13	“	"	PUNCT
dhrp-29	24	14	drug	drug	NOUN
dhrp-29	24	15	of	of	ADP
dhrp-29	24	16	interest	interest	NOUN
dhrp-29	24	17	”	"	PUNCT
dhrp-29	24	18	as	as	ADP
dhrp-29	24	19	an	an	DET
dhrp-29	24	20	oral	oral	ADJ
dhrp-29	24	21	agent	agent	NOUN
dhrp-29	24	22	to	to	PART
dhrp-29	24	23	treat	treat	VERB
dhrp-29	24	24	patients	patient	NOUN
dhrp-29	24	25	with	with	ADP
dhrp-29	24	26	mild	mild	ADJ
dhrp-29	24	27	-	-	PUNCT
dhrp-29	24	28	moderate	moderate	ADJ
dhrp-29	24	29	covid-19	covid-19	PROPN
dhrp-29	24	30	.	.	PUNCT
dhrp-29	25	1	while	while	SCONJ
dhrp-29	25	2	this	this	PRON
dhrp-29	25	3	is	be	AUX
dhrp-29	25	4	indeed	indeed	ADV
dhrp-29	25	5	very	very	ADV
dhrp-29	25	6	encouraging	encouraging	ADJ
dhrp-29	25	7	,	,	PUNCT
dhrp-29	25	8	submission	submission	NOUN
dhrp-29	25	9	/	/	SYM
dhrp-29	25	10	review	review	NOUN
dhrp-29	25	11	of	of	ADP
dhrp-29	25	12	data	datum	NOUN
dhrp-29	25	13	by	by	ADP
dhrp-29	25	14	the	the	DET
dhrp-29	25	15	fda	fda	PROPN
dhrp-29	25	16	and	and	CCONJ
dhrp-29	25	17	other	other	ADJ
dhrp-29	25	18	regulatory	regulatory	ADJ
dhrp-29	25	19	agencies	agency	NOUN
dhrp-29	25	20	along	along	ADP
dhrp-29	25	21	with	with	ADP
dhrp-29	25	22	publication	publication	NOUN
dhrp-29	25	23	of	of	ADP
dhrp-29	25	24	long	long	ADJ
dhrp-29	25	25	-	-	PUNCT
dhrp-29	25	26	term	term	NOUN
dhrp-29	25	27	follow	follow	NOUN
dhrp-29	25	28	-	-	PUNCT
dhrp-29	25	29	up	up	NOUN
dhrp-29	25	30	of	of	ADP
dhrp-29	25	31	ideally	ideally	ADV
dhrp-29	25	32	a	a	DET
dhrp-29	25	33	larger	large	ADJ
dhrp-29	25	34	cohort	cohort	NOUN
dhrp-29	25	35	of	of	ADP
dhrp-29	25	36	patients	patient	NOUN
dhrp-29	25	37	in	in	ADP
dhrp-29	25	38	peer	peer	NOUN
dhrp-29	25	39	-	-	PUNCT
dhrp-29	25	40	reviewed	review	VERB
dhrp-29	25	41	journal	journal	NOUN
dhrp-29	25	42	is	be	AUX
dhrp-29	25	43	quintessential	quintessential	ADJ
dhrp-29	25	44	to	to	PART
dhrp-29	25	45	unequivocally	unequivocally	ADV
dhrp-29	25	46	establish	establish	VERB
dhrp-29	25	47	the	the	DET
dhrp-29	25	48	efficacy	efficacy	NOUN
dhrp-29	25	49	of	of	ADP
dhrp-29	25	50	molnupiravir	molnupiravir	PROPN
dhrp-29	25	51	in	in	ADP
dhrp-29	25	52	the	the	DET
dhrp-29	25	53	oral	oral	ADJ
dhrp-29	25	54	treatment	treatment	NOUN
dhrp-29	25	55	of	of	ADP
dhrp-29	25	56	non	non	ADJ
dhrp-29	25	57	-	-	ADJ
dhrp-29	25	58	hospitalized	hospitalize	VERB
dhrp-29	25	59	high	high	ADJ
dhrp-29	25	60	-	-	PUNCT
dhrp-29	25	61	risk	risk	NOUN
dhrp-29	25	62	patients	patient	NOUN
dhrp-29	25	63	with	with	ADP
dhrp-29	25	64	mildmoderate	mildmoderate	PROPN
dhrp-29	25	65	sars	sar	NOUN
dhrp-29	25	66	-	-	PUNCT
dhrp-29	25	67	cov-2	cov-2	PART
dhrp-29	25	68	infection	infection	NOUN
dhrp-29	25	69	.	.	PUNCT
dhrp-29	26	1	references	reference	NOUN
dhrp-29	26	2	1	1	NUM
dhrp-29	26	3	.	.	PUNCT
dhrp-29	27	1	covid-19	covid-19	PROPN
dhrp-29	27	2	dashboard	dashboard	NOUN
dhrp-29	27	3	.	.	PUNCT
dhrp-29	28	1	john	john	PROPN
dhrp-29	28	2	hopkins	hopkins	PROPN
dhrp-29	28	3	university	university	PROPN
dhrp-29	28	4	of	of	ADP
dhrp-29	28	5	medicine	medicine	NOUN
dhrp-29	28	6	.	.	PUNCT
dhrp-29	29	1	2021	2021	NUM
dhrp-29	29	2	.	.	PUNCT
dhrp-29	30	1	https://coronavirus.jhu.edu/map.html	https://coronavirus.jhu.edu/map.html	PROPN
dhrp-29	30	2	(	(	PUNCT
dhrp-29	30	3	accessed	access	VERB
dhrp-29	30	4	october	october	PROPN
dhrp-29	30	5	02	02	NUM
dhrp-29	30	6	,	,	PUNCT
dhrp-29	30	7	2021	2021	NUM
dhrp-29	30	8	;	;	PUNCT
dhrp-29	30	9	21:48	21:48	NUM
dhrp-29	30	10	p.m.	p.m.	NOUN
dhrp-29	30	11	cst	cst	PROPN
dhrp-29	30	12	)	)	PUNCT
dhrp-29	30	13	2	2	NUM
dhrp-29	30	14	.	.	X
dhrp-29	30	15	fda	fda	PROPN
dhrp-29	30	16	approves	approve	VERB
dhrp-29	30	17	first	first	ADJ
dhrp-29	30	18	covid-19	covid-19	PROPN
dhrp-29	30	19	vaccine	vaccine	NOUN
dhrp-29	30	20	.	.	PUNCT
dhrp-29	31	1	2021	2021	NUM
dhrp-29	31	2	.	.	PUNCT
dhrp-29	32	1	https://www.fda.gov/news-events/press-announcements/fdaapproves-first-covid-19-vaccine	https://www.fda.gov/news-events/press-announcements/fdaapproves-first-covid-19-vaccine	PROPN
dhrp-29	32	2	3	3	NUM
dhrp-29	32	3	.	.	PUNCT
dhrp-29	32	4	available	available	ADJ
dhrp-29	32	5	covid-19	covid-19	PROPN
dhrp-29	32	6	treatment	treatment	NOUN
dhrp-29	32	7	option	option	NOUN
dhrp-29	32	8	.	.	PUNCT
dhrp-29	33	1	2021	2021	NUM
dhrp-29	33	2	.	.	PUNCT
dhrp-29	34	1	https://combatcovid.hhs.gov/i-have-covid-19-now/availablecovid-19-treatment-options	https://combatcovid.hhs.gov/i-have-covid-19-now/availablecovid-19-treatment-option	NOUN
dhrp-29	34	2	4	4	NUM
dhrp-29	34	3	.	.	X
dhrp-29	34	4	nazario	nazario	PROPN
dhrp-29	34	5	-	-	PUNCT
dhrp-29	34	6	toole	toole	PROPN
dhrp-29	34	7	ae	ae	PROPN
dhrp-29	34	8	,	,	PUNCT
dhrp-29	34	9	xia	xia	PROPN
dhrp-29	34	10	h	h	PROPN
dhrp-29	34	11	,	,	PUNCT
dhrp-29	34	12	gibbons	gibbon	NOUN
dhrp-29	35	1	tf	tf	X
dhrp-29	35	2	.	.	PUNCT
dhrp-29	36	1	whole	whole	ADJ
dhrp-29	36	2	-	-	PUNCT
dhrp-29	36	3	genome	genome	NOUN
dhrp-29	36	4	sequencing	sequencing	NOUN
dhrp-29	36	5	of	of	ADP
dhrp-29	36	6	sars	sar	NOUN
dhrp-29	36	7	-	-	PUNCT
dhrp-29	36	8	cov-2	cov-2	NUM
dhrp-29	36	9	:	:	PUNCT
dhrp-29	36	10	using	use	VERB
dhrp-29	36	11	phylogeny	phylogeny	NOUN
dhrp-29	36	12	and	and	CCONJ
dhrp-29	36	13	structural	structural	ADJ
dhrp-29	36	14	modeling	modeling	NOUN
dhrp-29	36	15	to	to	PART
dhrp-29	36	16	contextualize	contextualize	VERB
dhrp-29	36	17	local	local	ADJ
dhrp-29	36	18	viral	viral	ADJ
dhrp-29	36	19	evolution	evolution	NOUN
dhrp-29	36	20	[	[	X
dhrp-29	36	21	published	publish	VERB
dhrp-29	36	22	online	online	ADV
dhrp-29	36	23	ahead	ahead	ADV
dhrp-29	36	24	of	of	ADP
dhrp-29	36	25	print	print	NOUN
dhrp-29	36	26	,	,	PUNCT
dhrp-29	36	27	2021	2021	NUM
dhrp-29	36	28	feb	feb	NOUN
dhrp-29	36	29	20	20	NUM
dhrp-29	36	30	]	]	PUNCT
dhrp-29	36	31	.	.	PUNCT
dhrp-29	37	1	mil	mil	PROPN
dhrp-29	37	2	med	me	VERB
dhrp-29	37	3	.	.	PROPN
dhrp-29	37	4	2021	2021	NUM
dhrp-29	37	5	;	;	PUNCT
dhrp-29	37	6	usab031	usab031	PROPN
dhrp-29	37	7	.	.	PUNCT
dhrp-29	37	8	doi:10.1093	doi:10.1093	PROPN
dhrp-29	37	9	/	/	SYM
dhrp-29	37	10	milmed	milme	VERB
dhrp-29	37	11	/	/	SYM
dhrp-29	37	12	usab031	usab031	PROPN
dhrp-29	37	13	5	5	NUM
dhrp-29	37	14	.	.	PUNCT
dhrp-29	38	1	fischer	fischer	PROPN
dhrp-29	38	2	w	w	PROPN
dhrp-29	38	3	,	,	PUNCT
dhrp-29	38	4	eron	eron	PROPN
dhrp-29	38	5	jj	jj	PROPN
dhrp-29	38	6	,	,	PUNCT
dhrp-29	38	7	holman	holman	PROPN
dhrp-29	38	8	w	w	PROPN
dhrp-29	38	9	,	,	PUNCT
dhrp-29	38	10	cohen	cohen	PROPN
dhrp-29	38	11	ms	ms	PROPN
dhrp-29	38	12	,	,	PUNCT
dhrp-29	38	13	fang	fang	PROPN
dhrp-29	38	14	l	l	NOUN
dhrp-29	38	15	,	,	PUNCT
dhrp-29	38	16	szewczyk	szewczyk	ADJ
dhrp-29	38	17	lj	lj	ADV
dhrp-29	38	18	,	,	PUNCT
dhrp-29	38	19	sheahan	sheahan	ADP
dhrp-29	38	20	tp	tp	NOUN
dhrp-29	38	21	,	,	PUNCT
dhrp-29	38	22	baric	baric	ADJ
dhrp-29	38	23	r	r	NOUN
dhrp-29	38	24	,	,	PUNCT
dhrp-29	38	25	mollan	mollan	PROPN
dhrp-29	38	26	kr	kr	PROPN
dhrp-29	38	27	,	,	PUNCT
dhrp-29	38	28	wolfe	wolfe	PROPN
dhrp-29	38	29	cr	cr	PROPN
dhrp-29	38	30	,	,	PUNCT
dhrp-29	38	31	duke	duke	PROPN
dhrp-29	38	32	er	er	INTJ
dhrp-29	38	33	,	,	PUNCT
dhrp-29	38	34	azizad	azizad	NOUN
dhrp-29	38	35	mm	mm	INTJ
dhrp-29	38	36	,	,	PUNCT
dhrp-29	38	37	borroto	borroto	ADJ
dhrp-29	38	38	-	-	PUNCT
dhrp-29	38	39	esoda	esoda	PROPN
dhrp-29	38	40	k	k	PROPN
dhrp-29	38	41	,	,	PUNCT
dhrp-29	38	42	wohl	wohl	PROPN
dhrp-29	38	43	da	da	PROPN
dhrp-29	38	44	,	,	PUNCT
dhrp-29	38	45	loftis	loftis	PROPN
dhrp-29	38	46	aj	aj	PROPN
dhrp-29	38	47	,	,	PUNCT
dhrp-29	38	48	alabanza	alabanza	NOUN
dhrp-29	38	49	p	p	NOUN
dhrp-29	38	50	,	,	PUNCT
dhrp-29	38	51	lipansky	lipansky	ADJ
dhrp-29	38	52	f	f	NOUN
dhrp-29	38	53	,	,	PUNCT
dhrp-29	38	54	painter	painter	NOUN
dhrp-29	38	55	wp	wp	PROPN
dhrp-29	38	56	.	.	PUNCT
dhrp-29	39	1	molnupiravir	molnupiravir	PROPN
dhrp-29	39	2	,	,	PUNCT
dhrp-29	39	3	an	an	DET
dhrp-29	39	4	oral	oral	ADJ
dhrp-29	39	5	antiviral	antiviral	ADJ
dhrp-29	39	6	treatment	treatment	NOUN
dhrp-29	39	7	for	for	ADP
dhrp-29	39	8	covid-19	covid-19	PROPN
dhrp-29	39	9	.	.	PUNCT
dhrp-29	39	10	medrxiv	medrxiv	PROPN
dhrp-29	40	1	[	[	X
dhrp-29	40	2	preprint	preprint	NOUN
dhrp-29	40	3	]	]	X
dhrp-29	40	4	.	.	PUNCT
dhrp-29	41	1	2021	2021	NUM
dhrp-29	41	2	jun	jun	PROPN
dhrp-29	41	3	17:2021.06.17.21258639	17:2021.06.17.21258639	NUM
dhrp-29	41	4	.	.	PUNCT
dhrp-29	42	1	doi	doi	NOUN
dhrp-29	42	2	:	:	PUNCT
dhrp-29	42	3	10.1101/2021.06.17.21258639	10.1101/2021.06.17.21258639	NUM
dhrp-29	42	4	.	.	PUNCT
dhrp-29	43	1	pmid	pmid	NOUN
dhrp-29	43	2	:	:	PUNCT
dhrp-29	43	3	34159342	34159342	NUM
dhrp-29	43	4	;	;	PUNCT
dhrp-29	43	5	pmcid	pmcid	NOUN
dhrp-29	43	6	:	:	PUNCT
dhrp-29	43	7	pmc8219109	pmc8219109	ADJ
dhrp-29	43	8	.	.	PUNCT
dhrp-29	44	1	6	6	X
dhrp-29	44	2	.	.	X
dhrp-29	44	3	merck	merck	PROPN
dhrp-29	44	4	and	and	CCONJ
dhrp-29	44	5	ridgeback	ridgeback	PROPN
dhrp-29	44	6	’s	’s	PART
dhrp-29	44	7	investigational	investigational	ADJ
dhrp-29	44	8	oral	oral	ADJ
dhrp-29	44	9	antiviral	antiviral	NOUN
dhrp-29	44	10	molnupiravir	molnupiravir	PROPN
dhrp-29	44	11	reduced	reduce	VERB
dhrp-29	44	12	the	the	DET
dhrp-29	44	13	risk	risk	NOUN
dhrp-29	44	14	of	of	ADP
dhrp-29	44	15	hospitalization	hospitalization	NOUN
dhrp-29	44	16	or	or	CCONJ
dhrp-29	44	17	death	death	NOUN
dhrp-29	44	18	by	by	ADP
dhrp-29	44	19	approximately	approximately	ADV
dhrp-29	44	20	50	50	NUM
dhrp-29	44	21	percent	percent	NOUN
dhrp-29	44	22	compared	compare	VERB
dhrp-29	44	23	to	to	ADP
dhrp-29	44	24	placebo	placebo	NOUN
dhrp-29	44	25	for	for	ADP
dhrp-29	44	26	patients	patient	NOUN
dhrp-29	44	27	with	with	ADP
dhrp-29	44	28	mild	mild	ADJ
dhrp-29	44	29	or	or	CCONJ
dhrp-29	44	30	moderate	moderate	ADJ
dhrp-29	44	31	covid-19	covid-19	PROPN
dhrp-29	44	32	in	in	ADP
dhrp-29	44	33	positive	positive	ADJ
dhrp-29	44	34	interim	interim	ADJ
dhrp-29	44	35	analysis	analysis	NOUN
dhrp-29	44	36	of	of	ADP
dhrp-29	44	37	phase	phase	NOUN
dhrp-29	44	38	3	3	NUM
dhrp-29	44	39	study	study	NOUN
dhrp-29	44	40	.	.	PUNCT
dhrp-29	45	1	oct	oct	PROPN
dhrp-29	45	2	01	01	NUM
dhrp-29	45	3	,	,	PUNCT
dhrp-29	45	4	2021	2021	NUM
dhrp-29	45	5	.	.	PUNCT
dhrp-29	46	1	https://www.merck.com/news/merck-and-ridgebacksinvestigational-oral-antiviral-molnupiravir-reduced-the-risk-ofhospitalization-or-death-by-approximately-50-percentcompared-to-placebo-for-patients-with-mild-or-moderat/	https://www.merck.com/news/merck-and-ridgebacksinvestigational-oral-antiviral-molnupiravir-reduced-the-risk-ofhospitalization-or-death-by-approximately-50-percentcompared-to-placebo-for-patients-with-mild-or-moderat/	PROPN
dhrp-29	46	2	7	7	NUM
dhrp-29	46	3	.	.	PUNCT
dhrp-29	46	4	toots	toot	VERB
dhrp-29	46	5	m	m	PROPN
dhrp-29	46	6	,	,	PUNCT
dhrp-29	46	7	yoon	yoon	PROPN
dhrp-29	46	8	jj	jj	PROPN
dhrp-29	46	9	,	,	PUNCT
dhrp-29	46	10	cox	cox	PROPN
dhrp-29	46	11	rm	rm	PROPN
dhrp-29	46	12	,	,	PUNCT
dhrp-29	46	13	hart	hart	PROPN
dhrp-29	46	14	m	m	PROPN
dhrp-29	46	15	,	,	PUNCT
dhrp-29	46	16	sticher	sticher	PROPN
dhrp-29	46	17	zm	zm	PROPN
dhrp-29	46	18	,	,	PUNCT
dhrp-29	46	19	makhsous	makhsous	ADJ
dhrp-29	46	20	n	n	CCONJ
dhrp-29	46	21	,	,	PUNCT
dhrp-29	46	22	plesker	plesker	ADJ
dhrp-29	46	23	r	r	NOUN
dhrp-29	46	24	,	,	PUNCT
dhrp-29	46	25	barrena	barrena	X
dhrp-29	46	26	ah	ah	INTJ
dhrp-29	46	27	,	,	PUNCT
dhrp-29	46	28	reddy	reddy	PROPN
dhrp-29	46	29	pg	pg	PROPN
dhrp-29	46	30	,	,	PUNCT
dhrp-29	46	31	mitchell	mitchell	PROPN
dhrp-29	46	32	dg	dg	PROPN
dhrp-29	46	33	,	,	PUNCT
dhrp-29	46	34	shean	shean	PROPN
dhrp-29	46	35	rc	rc	PROPN
dhrp-29	46	36	,	,	PUNCT
dhrp-29	46	37	bluemling	bluemle	VERB
dhrp-29	46	38	gr	gr	PROPN
dhrp-29	46	39	,	,	PUNCT
dhrp-29	46	40	kolykhalov	kolykhalov	PROPN
dhrp-29	46	41	aa	aa	NOUN
dhrp-29	46	42	,	,	PUNCT
dhrp-29	46	43	greninger	greninger	PROPN
dhrp-29	46	44	al	al	PROPN
dhrp-29	46	45	,	,	PUNCT
dhrp-29	46	46	natchus	natchus	VERB
dhrp-29	46	47	mg	mg	PROPN
dhrp-29	46	48	,	,	PUNCT
dhrp-29	46	49	painter	painter	NOUN
dhrp-29	46	50	gr	gr	PROPN
dhrp-29	46	51	,	,	PUNCT
dhrp-29	46	52	plemper	plemper	NOUN
dhrp-29	46	53	rk	rk	NOUN
dhrp-29	46	54	.	.	NOUN
dhrp-29	46	55	characterization	characterization	NOUN
dhrp-29	46	56	of	of	ADP
dhrp-29	46	57	orally	orally	ADV
dhrp-29	46	58	efficacious	efficacious	ADJ
dhrp-29	46	59	influenza	influenza	NOUN
dhrp-29	46	60	drug	drug	NOUN
dhrp-29	46	61	with	with	ADP
dhrp-29	46	62	high	high	ADJ
dhrp-29	46	63	resistance	resistance	NOUN
dhrp-29	46	64	barrier	barrier	NOUN
dhrp-29	46	65	in	in	ADP
dhrp-29	46	66	ferrets	ferret	NOUN
dhrp-29	46	67	and	and	CCONJ
dhrp-29	46	68	human	human	ADJ
dhrp-29	46	69	airway	airway	NOUN
dhrp-29	46	70	epithelia	epithelia	PROPN
dhrp-29	46	71	.	.	PUNCT
dhrp-29	47	1	sci	sci	PROPN
dhrp-29	47	2	transl	transl	PROPN
dhrp-29	47	3	med	med	PROPN
dhrp-29	47	4	.	.	PROPN
dhrp-29	48	1	2019	2019	NUM
dhrp-29	48	2	oct	oct	PROPN
dhrp-29	48	3	23;11(515	23;11(515	NUM
dhrp-29	48	4	):	):	PUNCT
dhrp-29	48	5	eaax5866	eaax5866	PROPN
dhrp-29	48	6	.	.	PUNCT
dhrp-29	48	7	doi	doi	PROPN
dhrp-29	48	8	:	:	PUNCT
dhrp-29	48	9	10.1126	10.1126	NUM
dhrp-29	48	10	/	/	SYM
dhrp-29	48	11	scitranslmed	scitranslme	VERB
dhrp-29	48	12	.	.	PUNCT
dhrp-29	49	1	aax5866	aax5866	PROPN
dhrp-29	49	2	.	.	PUNCT
dhrp-29	50	1	pmid	pmid	NOUN
dhrp-29	50	2	:	:	PUNCT
dhrp-29	50	3	31645453	31645453	NUM
dhrp-29	50	4	;	;	PUNCT
dhrp-29	50	5	pmcid	pmcid	NOUN
dhrp-29	50	6	:	:	PUNCT
dhrp-29	50	7	pmc6848974	pmc6848974	PROPN
dhrp-29	50	8	sohail	sohail	PROPN
dhrp-29	50	9	rao	rao	PROPN
dhrp-29	50	10	,	,	PUNCT
dhrp-29	50	11	md	md	PROPN
dhrp-29	50	12	,	,	PUNCT
dhrp-29	50	13	ma	ma	PROPN
dhrp-29	50	14	,	,	PUNCT
dhrp-29	50	15	dphil	dphil	ADJ
dhrp-29	50	16	executive	executive	ADJ
dhrp-29	50	17	vice	vice	NOUN
dhrp-29	50	18	president	president	NOUN
dhrp-29	50	19	,	,	PUNCT
dhrp-29	50	20	dhr	dhr	PROPN
dhrp-29	50	21	health	health	PROPN
dhrp-29	50	22	,	,	PUNCT
dhrp-29	50	23	5501	5501	NUM
dhrp-29	50	24	s.	s.	PROPN
dhrp-29	50	25	mccoll	mccoll	PROPN
dhrp-29	50	26	road	road	PROPN
dhrp-29	50	27	,	,	PUNCT
dhrp-29	50	28	edinburg	edinburg	PROPN
dhrp-29	50	29	,	,	PUNCT
dhrp-29	50	30	texas	texas	PROPN
dhrp-29	50	31	president	president	PROPN
dhrp-29	50	32	&	&	CCONJ
dhrp-29	50	33	chief	chief	ADJ
dhrp-29	50	34	executive	executive	ADJ
dhrp-29	50	35	officer	officer	NOUN
dhrp-29	50	36	,	,	PUNCT
dhrp-29	50	37	dhr	dhr	PROPN
dhrp-29	50	38	health	health	PROPN
dhrp-29	50	39	institute	institute	PROPN
dhrp-29	50	40	for	for	ADP
dhrp-29	50	41	research	research	PROPN
dhrp-29	50	42	&	&	CCONJ
dhrp-29	50	43	development	development	PROPN
dhrp-29	50	44	,	,	PUNCT
dhrp-29	50	45	5323	5323	NUM
dhrp-29	50	46	s.	s.	PROPN
dhrp-29	50	47	mccoll	mccoll	PROPN
dhrp-29	50	48	road	road	PROPN
dhrp-29	50	49	,	,	PUNCT
dhrp-29	50	50	edinburg	edinburg	PROPN
dhrp-29	50	51	,	,	PUNCT
dhrp-29	50	52	texas	texas	PROPN
dhrp-29	50	53	corresponding	corresponding	PROPN
dhrp-29	50	54	author	author	NOUN
dhrp-29	50	55	email	email	NOUN
dhrp-29	50	56	:	:	PUNCT
dhrp-29	50	57	s.rao@dhr-rgv.com	s.rao@dhr-rgv.com	X
dhrp-29	50	58	disclosures	disclosure	NOUN
dhrp-29	50	59	:	:	PUNCT
dhrp-29	50	60	none	none	NOUN
dhrp-29	50	61	orcid	orcid	NOUN
dhrp-29	50	62	:	:	PUNCT
dhrp-29	50	63	sohail	sohail	PROPN
dhrp-29	50	64	rao	rao	PROPN
dhrp-29	50	65	:	:	PUNCT
dhrp-29	50	66	https://orcid.org/0000-0001-50279992	https://orcid.org/0000-0001-50279992	PROPN
dhrp-29	50	67	manish	manish	PROPN
dhrp-29	50	68	singh	singh	PROPN
dhrp-29	50	69	,	,	PUNCT
dhrp-29	50	70	md	md	PROPN
dhrp-29	50	71	,	,	PUNCT
dhrp-29	50	72	facs	facs	PROPN
dhrp-29	50	73	chief	chief	ADJ
dhrp-29	50	74	executive	executive	ADJ
dhrp-29	50	75	officer	officer	NOUN
dhrp-29	50	76	,	,	PUNCT
dhrp-29	50	77	dhr	dhr	PROPN
dhrp-29	50	78	health	health	PROPN
dhrp-29	50	79	,	,	PUNCT
dhrp-29	50	80	5501	5501	NUM
dhrp-29	50	81	s.	s.	PROPN
dhrp-29	50	82	mccoll	mccoll	PROPN
dhrp-29	50	83	road	road	PROPN
dhrp-29	50	84	,	,	PUNCT
dhrp-29	50	85	edinburg	edinburg	PROPN
dhrp-29	50	86	,	,	PUNCT
dhrp-29	50	87	texas	texas	PROPN
dhrp-29	50	88	disclosures	disclosure	NOUN
dhrp-29	50	89	:	:	PUNCT
dhrp-29	50	90	none	none	NOUN
dhrp-29	50	91	orcid	orcid	NOUN
dhrp-29	50	92	:	:	PUNCT
dhrp-29	51	1	manish	manish	PROPN
dhrp-29	51	2	singh	singh	PROPN
dhrp-29	51	3	:	:	PUNCT
dhrp-29	51	4	https://orcid.org/0000-00034146-3282	https://orcid.org/0000-00034146-3282	PROPN
dhrp-29	52	1	https://coronavirus.jhu.edu/map.html	https://coronavirus.jhu.edu/map.html	PROPN
dhrp-29	52	2	https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine	https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine	PROPN
dhrp-29	52	3	https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine	https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine	PROPN
dhrp-29	52	4	https://combatcovid.hhs.gov/i-have-covid-19-now/available-covid-19-treatment-options	https://combatcovid.hhs.gov/i-have-covid-19-now/available-covid-19-treatment-option	NOUN
dhrp-29	52	5	https://combatcovid.hhs.gov/i-have-covid-19-now/available-covid-19-treatment-options	https://combatcovid.hhs.gov/i-have-covid-19-now/available-covid-19-treatment-option	VERB
dhrp-29	52	6	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	PROPN
dhrp-29	52	7	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	PROPN
dhrp-29	52	8	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	PROPN
dhrp-29	52	9	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/	PROPN
dhrp-29	52	10	mailto:s.rao@dhr-rgv.com	mailto:s.rao@dhr-rgv.com	PROPN
dhrp-29	52	11	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-29	52	12	https://orcid.org/0000-0001-5027-9992	https://orcid.org/0000-0001-5027-9992	PROPN
dhrp-29	52	13	https://orcid.org/0000-0003-4146-3282	https://orcid.org/0000-0003-4146-3282	PROPN
dhrp-29	52	14	https://orcid.org/0000-0003-4146-3282	https://orcid.org/0000-0003-4146-3282	PROPN